SFDA Regulations on MDMA: Significant and Non-significant Changes Explained
The SFDA Regulations on MDMA require medical device manufacturers and other responsible parties to evaluate changes made to medical devices holding a Medical Device Marketing Authorization (MDMA) in Saudi Arabia. The Saudi Food and Drug Authority (SFDA) classifies applicable changes based on their potential impact on the safety and effectiveness of the medical device.
Under SFDA guidance, changes to an MDMA-registered medical device are generally assessed as significant or non-significant changes. Significant changes must be reported to SFDA within 10 days of the occurrence of the change and require SFDA approval before affected devices are supplied. Non-significant changes must be notified to SFDA within 30 days and do not require prior approval in the same manner.
Talk to our experts
The SFDA Regulations on MDMA cover changes related to intended use and labeling, critical suppliers, quality management systems, manufacturing processes, facilities and equipment, software, sterilization, device design, materials, safety, and performance.
This guide explains the SFDA requirements for significant and non-significant medical device changes, reporting timelines, examples, classification considerations, and compliance obligations for manufacturers marketing medical devices in Saudi Arabia.
Must Read: Medical Device Registration in Saudi Arabia
What Are the SFDA Regulations on MDMA?
The SFDA’s guidance on MDMA significant and non-significant changes explains how manufacturers should evaluate modifications made to medical devices that have an MDMA.
The purpose of the requirements is to ensure that changes made after authorization do not introduce unacceptable risks or negatively affect the safety and performance of the medical device.
Manufacturers should have documented procedures within their quality management system for:
- Identifying proposed changes
- Assessing the potential impact of changes
- Categorizing changes as significant or non-significant
- Performing applicable verification and validation
- Maintaining change-control records
- Notifying SFDA within the applicable timeframe
- Obtaining approval when required
The classification should be based on the potential impact of the change on the safety and effectiveness of the medical device rather than simply the type of modification being made.
SFDA Significant vs Non-Significant Medical Device Changes
The key difference between significant and non-significant changes is the potential impact of the change on the safety and effectiveness of the device.
| Change category | Potential impact | SFDA notification | SFDA approval |
|---|---|---|---|
| Significant change | Could directly affect safety or effectiveness | Within 10 days | Required before supplying affected devices |
| Non-significant change | Could indirectly affect safety or effectiveness | Within 30 days | Prior approval is not required in the same manner |
| Change with no reasonably expected safety/effectiveness impact | No expected impact | Update at MDMA renewal where applicable | Not applicable as a change notification |
Manufacturers should document the rationale behind the classification and maintain supporting evidence within their change-control process.
What Is a Significant Change Under SFDA?
A significant change is a modification that could reasonably be expected to directly affect the safety or effectiveness of a medical device.
Examples may include changes that affect:
- Intended use
- Device design
- Critical manufacturing processes
- Sterilization
- Critical suppliers
- Software functions
- Materials
- Operating principles
- Safety or performance
- Important labeling information
Significant Changes to Intended Use and Labeling
Changes to the intended use or important information provided with a medical device can affect how the device is used and the risks associated with it.
Examples may include:
- Changes to the intended purpose
- Changes to the intended user
- Changes to indications for use
- Changes to contraindications
- Changes to warnings or precautions that are important for risk mitigation
- Changes from single-use to reusable status
- Changes to sterilization information
- Changes that introduce a new indication
Labeling changes that affect the safety or effectiveness of the device should therefore be carefully evaluated before implementation.
Not every labeling modification is necessarily significant. Changes involving artwork, color, font, or layout may be considered non-significant when they do not directly affect safety or effectiveness.
Significant Changes to Critical Suppliers
A change involving a critical supplier may be significant when the supplier provides materials, components, or services that can directly affect the safety or performance of the medical device.
Examples may include:
- Changing a critical raw material supplier
- Changing a supplier of a critical component
- Changing a supplier responsible for a critical manufacturing process
- Changing a supplier where the new material or component has different characteristics
Manufacturers should evaluate the impact of supplier changes through their supplier-control and change-control procedures.
Significant Changes to the Quality Management System
Changes to the quality management system may be significant when they affect critical validated processes or controls that are important for managing device-related risks.
Examples include:
- Changes to critical validated processes
- Changes to sterilization processes
- Changes to critical process parameters
- Changes to drug coating processes
- Changes to viral inactivation processes
- Changes to other validated processes where failure could affect safety or performance
Manufacturers should assess whether the proposed change requires additional validation or other evidence before implementation.
Significant Changes to Manufacturing Processes, Facilities, or Equipment
Manufacturing changes can be significant when they could directly affect the safety or performance of the medical device.
Examples include:
- Changing the equipment used for cutting when it changes device dimensions
- Changing molding or cutting processes
- Changing a critical manufacturing method
- Changing from casting to 3D printing for an implant
- Changing from manual to automated operation where the change may affect the device
- Changing packaging processes where device safety or performance may be affected
- Changing an outsourced manufacturing process
For example, changing an implant manufacturing process from casting to 3D printing can alter material properties, manufacturing characteristics, and device performance. Such a change requires an appropriate regulatory and technical assessment.
Schedule a Compliance Consultation
Accelerate Market Access with End-to-End Regulatory Guidance
Non-Significant Manufacturing Changes
A non-significant change is a modification that could reasonably be expected to indirectly affect the safety or effectiveness of the medical device.
Non-significant changes still need to be evaluated and documented by the manufacturer. They are not changes that can simply be implemented without assessment.
SFDA must be notified of a non-significant change within 30 days of the occurrence of the change.
Examples may include certain:
- Packaging changes
- Labeling artwork changes
- Test-method changes
- Minor software modifications
- Changes that maintain equivalent performance
- Changes that do not directly affect safety or effectiveness
The manufacturer should maintain objective evidence supporting the classification.
What Is a Non-Significant Change Under SFDA?
Changes to the quality management system may be significant when they affect critical validated processes or controls that are important for managing device-related risks.
Examples include:
- Changes to critical validated processes
- Changes to sterilization processes
- Changes to critical process parameters
- Changes to drug coating processes
- Changes to viral inactivation processes
- Changes to other validated processes where failure could affect safety or performance
Manufacturers should assess whether the proposed change requires additional validation or other evidence before implementation.
Significant and Non-Significant Software Changes
The SFDA guidance covers changes to both standalone medical device software and software embedded within a medical device.
Software changes should be evaluated carefully because modifications to software can affect device functionality, diagnostic performance, therapeutic functions, alarms, usability, or safety.
Examples of Significant Software Changes
Significant software changes may include:
- Changes that affect the control of the medical device
- Changes to an algorithm that affect device functionality or performance
- Addition of new software functions
- Addition of new applications
- Changes affecting diagnostic or therapeutic functions
- Changes to the operating system that affect device performance
- Changes to alarm functions
- Changes that affect the safety or effectiveness of the device
For example, changing an algorithm used to generate a diagnostic result could directly affect the performance of the medical device and therefore requires careful regulatory assessment.
Examples of Non-Significant Software Changes
Examples can include:
- A simple bug fix that corrects a display error
- Changes that disable a function without affecting other functions or device performance
- Minor user-interface appearance changes with minimal or no impact on performance
The manufacturer should still document the software change and demonstrate that the modification does not introduce an unacceptable safety or performance impact.
Significant Changes to Sterilization
Sterilization is a critical process for many medical devices. A modification to sterilization can directly affect product safety.
Examples of potentially significant changes include:
- Changing the sterilization method
- Changing critical sterilization parameters
- Changing the sterilization process
- Changing sterilization facilities or equipment where safety or effectiveness may be affected
For example, changing from one sterilization method to another can affect material compatibility, sterility assurance, residuals, packaging, and device performance.
Such changes require appropriate evaluation and validation before implementation.
Significant Changes to Device Design
Changes to medical device design can be significant when they affect safety, performance, intended use, or the risk profile of the product.
Manufacturers should consider changes to:
- Device dimensions
- Materials
- Components
- Design specifications
- Operating principles
- Energy input or output
- Control mechanisms
- Software
- Human factors
- Intended users
- Operating environment
- Performance characteristics
Design changes should be supported by appropriate verification and validation activities.
Depending on the nature of the change, additional performance, clinical, or other supporting evidence may be necessary.
Significant Changes to Materials
Material changes can affect the physical, chemical, biological, or functional characteristics of a medical device.
Examples may include:
- Changing a critical raw material
- Changing the material composition
- Changing a material that affects biocompatibility
- Changing a material used in an implant
- Changing a material that affects device performance
- Changing a coating or surface treatment
Manufacturers should evaluate whether the new material has characteristics equivalent to the original material and whether additional testing is necessary.
Changes Affecting Safety and Performance
The overall purpose of the SFDA change-control requirements is to ensure that modifications do not negatively affect the safety or performance of a medical device.
Manufacturers should consider whether a change could affect:
- Device safety
- Clinical performance
- Diagnostic accuracy
- Therapeutic performance
- Sterility
- Biocompatibility
- Electrical safety
- Mechanical performance
- Software performance
- Usability
- Shelf life
- Packaging integrity
- Risk management
If a change could directly affect safety or effectiveness, it may fall into the significant-change category.
How to Report Medical Device Changes to SFDA
Manufacturers should establish a formal change-control procedure for medical devices holding an MDMA.
A practical change-management process includes:
Step 1: Identify the proposed change
Clearly document what is being changed and why the change is required.
Step 2: Assess the impact
Evaluate whether the change can affect safety, effectiveness, performance, intended use, or risk management.
Step 3: Classify the change
Determine whether the modification is significant, non-significant, or a change that can be updated at MDMA renewal because it is not reasonably expected to affect safety or effectiveness.
Step 4: Complete verification and validation
Perform applicable testing, verification, validation, stability assessment, risk assessment, or other supporting activities.
Step 5: Document the assessment
Maintain records explaining:
- What changed
- Why it changed
- Risk assessment
- Verification and validation results
- Regulatory classification
- Supporting evidence
- Approval or notification records
Step 6: Notify SFDA
For a significant change, notify SFDA within 10 days and obtain the required approval before supplying affected devices.
For a non-significant change, notify SFDA within 30 days.
How Can Operon Strategist Help You With SFDA Compliance?
Operon Strategist can support medical device manufacturers with:
- SFDA Medical Device Registration: Support for MDMA applications and regulatory submissions.
- Change Assessment: Evaluate proposed medical device changes and determine whether they are significant or non-significant.
- SFDA Change Notification: Assist with preparing and submitting required notifications within the applicable timelines.
- Regulatory Documentation: Prepare and review technical and regulatory documentation required for SFDA compliance.
- Medical Device Classification: Help determine the applicable SFDA classification and regulatory pathway.
- QMS & ISO 13485 Consulting: Support manufacturers in establishing and maintaining quality management systems.
- Regulatory Strategy: Develop a suitable regulatory pathway for entering and maintaining products in the Saudi Arabian market.
- Post-Registration Support: Assist with ongoing regulatory requirements, including product changes and compliance activities.
- End-to-End Regulatory Support: Provide guidance throughout the SFDA registration, change management, and compliance process.
Ensure Seamless Regulatory Compliance for Your Device
Get Your Medical Device Market-Ready with Expert Regulatory Support
FAQ's
What is a Medical Device Park?
A dedicated zone with shared infrastructure for medical device manufacturing.
What are the benefits?
Lower cost, faster setup, shared facilities, and easier compliance.
Is CDSCO approval required?
Yes, it is mandatory for manufacturing and selling medical devices in India.
Which are the top parks?
AMTZ, Telangana, Tamil Nadu, and YEIDA are leading parks.
Which are the top parks?
AMTZ, Telangana, Tamil Nadu, and YEIDA are leading parks.